PCM
GLUE icon

Prelude Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Prelude Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,473
Closed -$715K – 1351
2026
Q1 		$715K Buy
+43,473
New +$831K 0.05% 390
2025
Q4 		– Sell
-10,202
Closed -$75.6K – 1393
2025
Q3 		$75.6K Buy
+10,202
New +$54K 0.01% 1078

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Prelude Capital Management's GLUE Position: Q2 2026 in Review

Prelude Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 43,473 shares — an estimated $715K sold.

Prelude Capital Management first reported a position in GLUE in Q3 2025 and held it in 2 quarters. The position peaked at $715K in Q1 2026. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Prelude Capital Management reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 43,473 Monte Rosa Therapeutics shares in Q2 2026, an estimated $715K.
  • Prelude Capital Management first reported a position in Monte Rosa Therapeutics in Q3 2025 and held it in 2 quarters.
  • Prelude Capital Management's Monte Rosa Therapeutics position peaked at $715K in Q1 2026.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.